NCT05824975: A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 358 planned
- Started
- 30 May 2023
- Primary completion
- 12 Nov 2025
- Arms
- GI-102 subcutaneous (SC)
- Results
- None posted
- 24 Apr 2023: Trial registered
- 30 May 2023: Trial started